Carcinotech secures £1.6m to accelerate commercialisation and expand internationally.
TRICAPITAL led the investment round with backing from a syndicate of Scottish investors.
Share allotment filed at Companies House
Life sciences business manufacturing 3D printed tumours from cancer stem cells and primary cells for oncology research.
Edinburgh based life sciences company Carcinotech has raised £1.6m in new funding to accelerate its commercialisation and international expansion. The round was led by TRICAPITAL, with participation from Eos Advisory, SIS Ventures, Gabriel Investments, Alba Equity, and Scottish Enterprise.
The capital will support the company as it builds international partnerships across Europe and North America over the coming year. Carcinotech develops 3D printed tumour models using patient specific cells to assist with drug discovery and pre clinical testing.
From the founder
"Our next phase of growth will involve building international partnerships, growing the team, and appointing a scientific advisory committee to support the work of the main board."
Ishani Malhotra
CEO and founder at Carcinotech
Investor perspective
"Carcinotech is one of the most exciting early-stage companies to come out of the Scottish life sciences sector in recent times. We can already see traction and momentum, and look forward to actively supporting Ishani and her team as they continue to scale."
Moray Martin
Managing Partner, TRICAPITAL
Use of funds
- 01Expand into international markets
Investors
Moray Martin
TRICAPITAL
Gabriel Investment
Ana Stewart
Eos Advisory
Siobhan Moore
SIS Ventures
Alba Equity
Scottish Enterprise
Categories
About the company
Carcinotech
Carcinotech manufactures 3D printed tumours from cancer cells for oncology testing and research.